Intravenous therapy has become one of the fastest-growing service lines in outpatient medicine. Physicians across specialties are adding IV infusion programs to their practices, drawn by a combination of genuine clinical utility and strong patient demand. Unlike oral supplementation — which is subject to gastrointestinal absorption limits and metabolic processing — IV delivery achieves systemic concentrations of vitamins, minerals, and therapeutic compounds through a fundamentally different route. For patients and providers alike, that distinction matters.
This guide is intended to give licensed medical providers a general educational overview of the IV therapy landscape: what protocols are currently in use, what operational and regulatory considerations are commonly associated with establishing an infusion program, and what questions providers should be exploring with their own qualified clinical and legal advisors before launching. It does not constitute medical, clinical, or legal advice of any kind. All decisions about patient care, clinic protocols, and program structure should be made by qualified licensed professionals in accordance with applicable law and the standard of care.
Why IV Therapy Is Growing in Outpatient Settings
The interest in outpatient IV therapy reflects both shifting patient expectations and a growing body of clinical literature exploring the role of micronutrient repletion, antioxidant support, and targeted intravenous administration in wellness and disease management. Patients who have previously relied solely on oral supplementation are increasingly aware that intravenous delivery offers a different pharmacokinetic profile — and they are actively seeking providers who can offer it.
For medical practices, an IV therapy program can represent a meaningful service expansion. The patient population attracted to IV therapy tends to be health-engaged, interested in preventive and functional approaches, and receptive to building an ongoing provider relationship. Many practices find that infusion services complement their existing clinical offerings and support the kind of proactive, whole-patient care model that distinguishes wellness-oriented practices.
Common IV Therapy Protocols: An Educational Overview
The following summaries are intended to give providers a general familiarity with the protocols most commonly discussed in the IV therapy space. They are not clinical protocols, dosing guides, or treatment recommendations of any kind. Providers considering any of these infusion types should consult appropriate clinical literature, qualified medical advisors, and applicable regulatory guidance before developing their own practice-specific protocols.
Myers’ Cocktail
Originally developed by physician John Myers and later documented by Alan Gaby, MD in a widely referenced paper published in Alternative Medicine Review, the Myers’ Cocktail is the most recognized outpatient IV therapy formulation. It typically involves a combination of magnesium, calcium, B vitamins, and vitamin C in a sterile base. It has been discussed in the medical literature in connection with a range of conditions including fatigue, migraines, fibromyalgia, and immune support, among others. Providers interested in this protocol are encouraged to review the available published literature and consult with qualified clinical advisors regarding its appropriate use in their patient population.
High-Dose Vitamin C
High-dose intravenous vitamin C — at concentrations well above what is achievable through oral supplementation — has been the subject of clinical investigation in a variety of contexts, including integrative oncology and immune support. The NIH Office of Dietary Supplements provides a comprehensive overview of the pharmacokinetic distinction between oral and intravenous ascorbic acid at therapeutic concentrations. Providers considering vitamin C infusions should familiarize themselves with the existing clinical research, relevant patient screening considerations, and applicable clinical guidelines through qualified clinical resources and advisors.
NAD+ Infusions
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme involved in mitochondrial energy production, DNA repair, and cellular aging mechanisms. A growing body of peer-reviewed research available through PubMed explores its potential role in energy metabolism, cognitive support, and neurological recovery. Interest in intravenous NAD+ administration has grown in both functional medicine and addiction medicine settings. As with all IV therapy protocols, providers should consult the clinical literature and seek guidance from qualified medical advisors regarding appropriate patient selection and administration considerations before offering this service.
Hydration Therapy
IV hydration — the administration of sterile electrolyte-containing fluids intravenously — is among the most straightforward and widely understood IV therapy applications. It is used in outpatient settings to address dehydration associated with illness, physical exertion, travel, and similar causes. The patient population for hydration therapy tends to be broad, and many practices use it as an accessible entry point into their IV therapy service line.
Glutathione
Glutathione is the body’s primary endogenous antioxidant, produced in the liver and central to detoxification and immune regulation. Intravenous or intramuscular administration is commonly discussed in the clinical literature as a more effective delivery route than oral supplementation. IV glutathione is frequently discussed in the context of antioxidant support, liver health, and skin health, and is often administered as an adjunct to other infusion protocols.
Patient Selection: A Framework for Providers
Patient selection and intake screening for IV therapy programs are clinical matters that sit squarely within the provider’s scope of practice and professional responsibility. The considerations involved — including review of each patient’s medical history, current medications, existing conditions, and individual risk factors — require the independent clinical judgment of a licensed healthcare provider and cannot be reduced to a universal protocol.
Providers establishing an IV therapy program are encouraged to work with qualified clinical advisors to develop their own evidence-informed intake and screening processes, informed consent documentation, and criteria for patient eligibility. The following are general categories that the clinical literature commonly identifies as relevant areas of consideration in the IV therapy context — presented here for educational awareness only, and not as a clinical checklist or protocol of any kind:
- Medical and medication history review
- Known allergies or sensitivities relevant to infusion components
- Relevant laboratory and clinical findings, as determined by the treating provider
- Patient-specific factors identified through the provider’s own clinical evaluation
The appropriate scope and structure of patient screening is a clinical determination for each provider to make in consultation with qualified advisors and in accordance with the applicable standard of care.
Clinic Setup and Compliance Considerations
Establishing a compliant IV therapy program involves operational, regulatory, and legal considerations that vary by state and by practice type. The following is a general educational overview of the categories providers typically need to address. None of this constitutes legal, regulatory, or clinical advice — providers should consult qualified legal and clinical counsel before launching an infusion program.
Physical Space and Safety
Infusion suites are clinical spaces and should be designed and equipped accordingly. General considerations commonly discussed in the professional context include patient comfort and privacy, adequate space for clinical staff to move safely, and access to appropriate emergency equipment. State health department regulations and medical board guidance may specify additional requirements for settings where IV medications are administered. Providers should review all applicable state and federal requirements for their specific setting and practice type.
Staffing and Supervision
Questions about who may administer IV infusions, what level of physician supervision is required, and how clinical staff may operate within an infusion program are governed by state-specific scope-of-practice rules and medical board regulations that vary meaningfully from state to state. Providers are strongly encouraged to obtain clarity on their state’s specific requirements from a qualified regulatory attorney or by contacting their state medical board directly before making any staffing or supervision decisions.
Pharmaceutical Sourcing and Compliance
Many IV therapy protocols involve compounded preparations — formulations prepared by a licensed compounding pharmacy rather than manufactured as FDA-approved commercial products. Compounded IV preparations are not FDA-approved drugs and have not been evaluated by the FDA for safety, effectiveness, or quality. The FDA’s human drug compounding guidance provides important context on the regulatory framework that applies to compounded preparations. Providers should consult applicable state pharmacy board guidance, FDA guidance, and a qualified healthcare regulatory attorney to understand their sourcing obligations and ensure their practices are fully compliant.
Documentation
Clinical documentation for IV therapy should meet the same standards as any other clinical service offered by the practice. EHR systems used in outpatient settings can typically be configured to support infusion charting. Billing and coding for infusion services, particularly for any insurance-billed claims, involves specific requirements that providers should review carefully with qualified billing and compliance professionals.
Sourcing Pharmaceutical Compounds for Your Infusion Program
The quality and compliance of a provider’s pharmaceutical supply is a foundational element of any IV therapy program. Providers should consult applicable regulatory guidance and qualified legal counsel to understand the sourcing requirements that apply to their specific program and practice type, and should work with distribution partners who operate in accordance with those requirements.
Supply reliability is also a practical operational consideration. A distributor relationship built specifically for licensed medical providers — with consistent inventory, rapid shipping, and responsive account support — reduces administrative burden and supports uninterrupted patient care.
Learn More About NMR Meds Provider Accounts
National Medical Resources, Inc. (NMR Meds) is a licensed distributor of pharmaceutical and wellness products serving licensed healthcare providers across the United States. We supply pharmaceutical compounds used in IV therapy programs — including components for hydration, vitamin infusions, NAD+, and glutathione — at wholesale pricing with consistent inventory and rapid delivery to provider accounts.
NMR Meds does not provide medical advice, clinical protocols, regulatory guidance, or legal counsel of any kind. All clinical and regulatory decisions related to your infusion program are the responsibility of qualified licensed professionals and their advisors. Our role is to serve as a reliable, compliant supply partner for licensed providers who have already made those determinations.
Open your NMR Meds provider account today — and work with a pharmaceutical distribution partner that understands what licensed clinical practices need.
MEDICAL & LEGAL DISCLAIMER
The information contained in this article is intended for licensed healthcare providers and qualified medical professionals only. It is provided for general informational and educational purposes and does not constitute medical advice, clinical guidance, or a substitute for the independent professional judgment of a licensed physician or other qualified healthcare provider.
Nothing in this article should be construed as a recommendation to diagnose, treat, cure, or prevent any disease or medical condition, nor as guidance on prescribing or administering any pharmaceutical compound to any specific patient. All clinical decisions regarding patient eligibility, dosing, monitoring, and treatment should be made by a licensed healthcare provider based on the individual patient’s clinical presentation, medical history, and applicable standard of care.
COMPOUNDED MEDICATION DISCLOSURE: Compounded IV preparations, including but not limited to compounded NAD+, glutathione, Myers’ Cocktail formulations, and high-dose vitamin C, are not FDA-approved drugs and have not been evaluated by the U.S. Food and Drug Administration for safety, effectiveness, or quality. Compounded preparations are not generic versions of, and are not the same as or equivalent to, any FDA-approved product. Compounded medications may only be dispensed pursuant to a valid, patient-specific prescription issued by a licensed prescriber or through a properly licensed outsourcing facility in accordance with applicable federal and state law. Nothing in this article constitutes a claim that any compounded product is clinically proven, has been evaluated in clinical trials, or produces results equivalent to any FDA-approved drug.
The regulatory landscape governing compounded medications is subject to change. Information provided in this article reflects publicly available guidance as of the publication date and may not reflect the most current regulatory requirements. Readers are strongly encouraged to consult with a qualified healthcare regulatory attorney and to monitor updates from the U.S. Food and Drug Administration (FDA) and applicable state pharmacy and medical boards before initiating or modifying any compounding or dispensing program.
National Medical Resources, Inc. (NMR Meds) is a distributor of medical and wellness products to licensed healthcare providers. NMR Meds does not provide medical advice, clinical consultation, or legal guidance. References to specific products, dosing schedules, or clinical protocols in this article are for informational and educational purposes only and do not constitute an endorsement of any specific treatment approach.
© 2026 National Medical Resources, Inc. All rights reserved. This content is intended for licensed healthcare professionals and may not be reproduced or redistributed without written permission.